DiagnaMed Launches a Generative Artificial Intelligence Medical Chatbot, Dr. GenAI
TORONTO, June 15, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative AI healthcare company, is pleased to announce the launch of Dr. GenAI (https://drgen.ai), a generative artificial intelligence (“GenAI”) medical chatbot powered by OpenAI's ChatGPT for people seeking to take control of their overall health. Dr. GenAI is the Company’s third commercial product from its Health GenAI division, which is focused on developing and commercializing a suite of generative AI health applications.
Dr. GenAI is a personal medical chatbot designed to give people a new way to obtain fast and personalized medical information based on a person’s unique medical condition. Dr. GenAI offers natural, human-like chats and can be a part of everyday life for people seeking a better understanding of their symptoms or new health solution ideas. In addition, Dr. GenAI is ready to learn about a person using their medical information, such as physical traits, vitals, and lab test results. Dr. GenAI is not a replacement for doctors and can be prone to errors, but it aims to encourage a person to be more active in their overall health care.
Fabio Chianelli, Chairman and CEO of DiagnaMed, commented: “We are excited to launch our third generative AI health solution, Dr. GenAI, for people seeking health information based on their unique medical conditions. Dr. GenAI aligns with our objective of developing and commercializing OpenAI ChatGPT powered solutions for the healthcare market and incorporating them into our CERVAI™ generative AI brain health platform.”
Dr. GenAI is available for free for up to 20 messages per month. Users can upgrade their subscription to the PRO version for unlimited messages and early access to new features for
Dr. GenAI was born from the Company’s knowledge, development experience and features of its proprietary generative AI brain health platform, CERVAI™, targeting patients, licensed medical professionals, hospitals, and life science companies. Dr. GenAI will also be incorporated into the CERVAI™ platform, offering patients a full suite of solutions to improve their brain health.
According to Market.us, generative AI in the healthcare market is set to reach approximately USD
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF), a generative artificial intelligence healthcare solutions company, is focused on the development and commercialization of CERVAI™, a proprietary brain health AI platform, and Health GenAI, a suite of generative AI products for the healthcare market. Learn more at DiagnaMed.com.
For more information about DiagnaMed, please contact:
Fabio Chianelli
Chairman of the Board
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the three and six months ended March 31, 2023 (“MD&A”), dated May 29, 2023,which is available on the Company's profile at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/74f0ead9-212d-4231-b120-fe3971299211
